article thumbnail

NuChem Sciences becomes part of the Sygnature Group

Drug Discovery World

Founded in 2011, the company delivers discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology.

Science 130
article thumbnail

Sygnature Discovery accelerates global growth with major North American acquisition

Sygnature Discovery

Founded in 2011, NuChem Sciences delivers expert integrated and standalone discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

For example, in the screening stage of a project we are trying to find initial starting points for optimisation by our medicinal and computational chemistry colleagues. 2011) D67, 386-394) using PDB ID 4GV1 which was published as part of Addie et al. Capivasertib (orange) bound to the kinase domain of AKT (blue). Acta Cryst.

article thumbnail

The Book of Nimbus

LifeSciVC

The premise at the time was that putting computational chemistry in the primary position for new molecule ideation would upend the drug discovery paradigm. set up a “virtual project team,” leverage Schrödinger scientists to lead computational chemistry, and do all the wet work at CROs. It did just that.